75 studies found for:    Open Studies | "Eye Neoplasms"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting MRI in Diagnosing Solid Tumors of the Eye and Orbit
Condition: Eye Cancer
Intervention: Procedure: dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
2 Recruiting Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid
Condition: Eye Cancer
Interventions: Procedure: Lymphatic Mapping;   Procedure: SLN Mapping/Biopsy
3 Not yet recruiting MRI Perfusion Curves Typology and Orbital Tumors (PERFORM)
Condition: Orbital Tumor
Intervention:
4 Not yet recruiting MRI and Orbital Tumours (MEDORT)
Conditions: Orbital Tumor;   Orbital Pseudotumor
Intervention: Other: MRI
5 Recruiting Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Conditions: Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
Interventions: Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
6 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis
7 Not yet recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
8 Recruiting Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Stage IIA Uveal Melanoma;   Stage IIB Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma
Interventions: Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
9 Recruiting SPT Screening in Irradiated Hereditary Retinoblastoma Survivors
Condition: Retinoblastoma
Intervention: Device: Magnetic resonance imaging
10 Not yet recruiting Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Drug: lenalidomide;   Drug: romidepsin;   Other: laboratory biomarker analysis
11 Recruiting Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: BYL719
12 Recruiting Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Condition: Uveal Melanoma
Intervention: Drug: crizotinib
13 Recruiting Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
14 Recruiting Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Condition: Retinoblastoma
Interventions: Other: Skin Biopsy;   Other: Blood Draw
15 Recruiting CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
16 Recruiting Carboplatin Periocular Injection for Retinoblastoma
Condition: Retinoblastoma
Interventions: Drug: carboplatin periocular injection;   Drug: chemotherapy
17 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
18 Recruiting Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma
Conditions: Advanced Intra-Ocular Retinoblastoma;   Retinoblastoma
Interventions: Drug: Melphalan;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine
19 Recruiting Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Angiofollicular Lymphoid Hyperplasia;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Plasma Cell Myeloma;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Recruiting Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Condition: Unilateral Retinoblastoma
Intervention: Drug: Melphalan

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years